4.38Open4.38Pre Close0 Volume10 Open Interest4.00Strike Price0.00Turnover290.76%IV9.11%PremiumSep 20, 2024Expiry Date3.68Intrinsic Value100Multiplier21DDays to Expiry0.70Extrinsic Value100Contract SizeAmericanOptions Type0.9000Delta0.0324Gamma1.90Leverage Ratio-0.0226Theta0.0017Rho1.71Eff Leverage0.0033Vega
Terns Pharmaceuticals Stock Discussion
Larger Image: tradingview.com...
$Terns Pharmaceuticals (TERN.US)$
Terns Pharmaceuticals Highlights New Preclinical Data Supporting TERN-501 in Combination with a GLP-1R Agonist for Obesity at the ADA’s 84th Annual Scientific Sessions and Upcoming Conference Participation
Terns Pharmaceuticals announced new preclinical data supporting their compound TERN-501 in combination with a GLP-1 receptor agonist for treating obesity. The data was presented at the ADA’s 84th Annual Scientific Sessions. TERN-501, a highly selective THR-...
Larger Image: tradingview.com...
$Terns Pharmaceuticals (TERN.US)$
Larger Image: tradingview.com...
$Terns Pharmaceuticals (TERN.US)$
NEWS
Terns Pharmaceuticals Announces Data from Ongoing Phase 1 Pharmacokinetic Study of Allosteric BCR-ABL Inhibitor TERN-701 in Adult Healthy Volunteers and Highlights Potential for Competitive Differentiation
Larger Image: tradingview.com...
$Terns Pharmaceuticals (TERN.US)$
Larger Image: tradingview.com...
$Terns Pharmaceuticals (TERN.US)$
No comment yet